These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

684 related items for PubMed ID: 18543098

  • 1. Pattern of metastatic spread in triple-negative breast cancer.
    Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA.
    Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098
    [Abstract] [Full Text] [Related]

  • 2. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
    Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D.
    J Clin Oncol; 2006 Dec 20; 24(36):5652-7. PubMed ID: 17116942
    [Abstract] [Full Text] [Related]

  • 3. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
    Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A.
    Eur J Cancer; 2009 Nov 20; 45(16):2792-8. PubMed ID: 19643597
    [Abstract] [Full Text] [Related]

  • 4. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
    Kaplan HG, Malmgren JA, Atwood M.
    Breast J; 2009 Nov 20; 15(5):454-60. PubMed ID: 19671105
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G.
    Hum Pathol; 2006 Sep 20; 37(9):1217-26. PubMed ID: 16938528
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [A study on the relationship between breast cancer molecular classification and prognosis].
    Chen XS, Ma CD, Chen CM.
    Zhonghua Wai Ke Za Zhi; 2008 Sep 15; 46(18):1400-3. PubMed ID: 19094512
    [Abstract] [Full Text] [Related]

  • 16. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY.
    BMC Cancer; 2008 Oct 23; 8():307. PubMed ID: 18947390
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
    Flowers A, Chu QD, Panu L, Meschonat C, Caldito G, Lowery-Nordberg M, Li BD.
    Surgery; 2009 Aug 23; 146(2):220-6. PubMed ID: 19628077
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Triple-negative breast cancer in West Virginia.
    Abraham J, Flanagan M, Hazard H, Jubelirer S, Tirona MT, Vona-Davis L.
    W V Med J; 2009 Oct 23; 105 Spec No():54-9. PubMed ID: 19999267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.